US Supreme Court Permits Earlier Biosimilar Launches; Penalty For Declining Patent Dance Uncertain

Court says biosimilar sponsors may provide 180-day notice of marketing prior to FDA approval; Federal Circuit to decide if innovators can seek an injunction under state law if sponsors do not provide application and manufacturing information; Justice Breyer offers FDA invitation to weigh in.